Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company focusing on discovering, developing, and commercializing innovative medicines. It is headquartered in Foster City, California, and operates in more than 35 countries worldwide. Gilead Sciences, Inc. is developing treatments for HIV/AIDS, liver diseases, cancer, and other life-threatening illnesses.
Company Info
US3755581036
375558103
Jan 22, 1992
Highlights
$115.65B
$0.09
1,031.11
0.53
$28.30B
$22.07B
$3.92B
$60.24 - $98.08
$98.92
1.88%
3.21
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Gilead Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Gilead Sciences, Inc. had a return of 16.52% year-to-date (YTD) and 18.75% in the last 12 months. Over the past 10 years, Gilead Sciences, Inc. had an annualized return of 1.59%, while the S&P 500 had an annualized return of 11.01%, indicating that Gilead Sciences, Inc. did not perform as well as the benchmark.
GILD
16.52%
3.38%
46.17%
18.75%
10.76%
1.59%
^GSPC (Benchmark)
23.11%
-0.36%
7.02%
23.15%
12.80%
11.01%
Monthly Returns
The table below presents the monthly returns of GILD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -3.39% | -7.87% | 2.64% | -10.99% | -1.43% | 8.06% | 10.86% | 3.87% | 7.12% | 5.94% | 4.23% | 16.52% | |
| 2023 | -2.22% | -4.06% | 4.01% | -0.92% | -6.41% | 1.14% | -1.21% | 0.45% | -1.05% | 4.80% | -2.47% | 6.72% | -1.99% |
| 2022 | -5.41% | -12.06% | -0.32% | -0.18% | 9.29% | -3.50% | -3.33% | 6.23% | -1.70% | 27.18% | 11.94% | -1.44% | 23.63% |
| 2021 | 12.60% | -6.40% | 6.46% | -1.79% | 4.16% | 5.25% | -0.83% | 6.57% | -3.06% | -7.12% | 6.24% | 6.41% | 29.95% |
| 2020 | -2.74% | 9.75% | 8.79% | 12.36% | -7.35% | -0.26% | -9.63% | -4.00% | -4.34% | -7.98% | 4.33% | -2.89% | -6.70% |
| 2019 | 11.93% | -7.13% | 0.95% | 0.05% | -4.29% | 9.56% | -3.02% | -3.02% | 0.68% | 0.52% | 5.54% | -2.45% | 7.88% |
| 2018 | 16.97% | -6.05% | -3.56% | -4.19% | -6.69% | 5.95% | 9.87% | -2.70% | 2.75% | -11.70% | 5.51% | -12.32% | -9.92% |
| 2017 | 1.17% | -2.72% | -2.89% | 0.93% | -5.34% | 9.95% | 7.50% | 10.01% | -2.61% | -7.48% | -0.24% | -3.54% | 2.96% |
| 2016 | -17.98% | 5.12% | 5.79% | -3.97% | -1.30% | -3.64% | -4.74% | -1.37% | 1.56% | -6.94% | 0.10% | -2.21% | -27.59% |
| 2015 | 11.21% | -1.24% | -5.22% | 2.43% | 11.70% | 4.66% | 0.67% | -10.85% | -6.18% | 10.12% | -2.01% | -4.09% | 8.63% |
| 2014 | 7.39% | 2.65% | -14.41% | 10.77% | 3.47% | 2.09% | 10.42% | 17.49% | -1.03% | 5.21% | -10.43% | -6.04% | 25.51% |
| 2013 | 7.42% | 8.29% | 14.56% | 3.47% | 7.58% | -5.89% | 19.76% | -1.84% | 4.31% | 13.22% | 5.10% | 0.39% | 104.49% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GILD is 67, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Gilead Sciences, Inc. provided a 3.40% dividend yield over the last twelve months, with an annual payout of $3.08 per share. The company has been increasing its dividends for 8 consecutive years.
| Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $3.08 | $3.00 | $2.92 | $2.84 | $2.72 | $2.52 | $2.28 | $2.08 | $1.84 | $1.29 |
Dividend yield | 3.40% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% |
Monthly Dividends
The table displays the monthly dividend distributions for Gilead Sciences, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $0.00 | $0.00 | $0.77 | $3.08 |
| 2023 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $0.00 | $0.00 | $0.75 | $3.00 |
| 2022 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $0.00 | $0.00 | $0.73 | $2.92 |
| 2021 | $0.00 | $0.00 | $0.71 | $0.00 | $0.00 | $0.71 | $0.00 | $0.00 | $0.71 | $0.00 | $0.00 | $0.71 | $2.84 |
| 2020 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.68 | $0.00 | $0.00 | $0.68 | $2.72 |
| 2019 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.63 | $0.00 | $0.00 | $0.63 | $2.52 |
| 2018 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $2.28 |
| 2017 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $0.00 | $0.00 | $0.52 | $2.08 |
| 2016 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.47 | $1.84 |
| 2015 | $0.43 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.43 | $1.29 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Gilead Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Gilead Sciences, Inc. was 70.82%, occurring on Jun 6, 1994. Recovery took 300 trading sessions.
The current Gilead Sciences, Inc. drawdown is 6.59%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -70.82% | Jan 28, 1992 | 596 | Jun 6, 1994 | 300 | Aug 11, 1995 | 896 |
| -60.43% | Sep 26, 1997 | 234 | Aug 31, 1998 | 127 | Mar 4, 1999 | 361 |
| -59.67% | Sep 8, 1999 | 73 | Dec 20, 1999 | 169 | Aug 21, 2000 | 242 |
| -58.81% | Jan 29, 1996 | 117 | Jul 15, 1996 | 298 | Sep 17, 1997 | 415 |
| -53.46% | Sep 26, 2000 | 73 | Jan 9, 2001 | 91 | May 21, 2001 | 164 |
Volatility
Volatility Chart
The current Gilead Sciences, Inc. volatility is 5.57%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Gilead Sciences, Inc. compared to its peers in the Drug Manufacturers - General industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for GILD in comparison to other companies of the Drug Manufacturers - General industry. Currently, GILD has a PE value of 1,031.1. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for GILD in comparison to other companies of the Drug Manufacturers - General industry. Currently, GILD has a PEG value of 0.5. This PEG ratio falls in the average range for the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Gilead Sciences, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |